Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01365273
Other study ID # MPTO 04
Secondary ID
Status Completed
Phase Phase 4
First received May 27, 2011
Last updated January 17, 2014
Start date February 2011
Est. completion date December 2011

Study information

Verified date August 2012
Source Molnlycke Health Care AB
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

This investigation is an open, randomised investigation. Approximately 40 subjects in 4-5 centres in the US with deep-partial of full thickness burns in need of skin grafts will be enrolled.The subjects will be equally randomised to either treatment with Mepitel One or bridal veil together with staples.

The primary objective is to compare pain at the time of dressing change for the use of Mepitel One versus bridal veil together with staples on deep partial or full thickness burns requiring skin grafts.


Description:

Skin grafts are placed over excised areas of full thickness injuries and usually attached with sutures or staples. While useful in anchoring the graft in place, subjects often complain of pain from the staples as wound healing progresses.Pulling and sticking are common complaints.There is also a possibility that staples become embedded in the graft which leads to disruption of otherwise healed area, increased pain and anxiety for the subject as well as anxiety for the staff.

Graft take can be optimized with appropriate medical management. Use of non-adherent dressings to protect the graft is customary. Various types of netting-style are used, such as Bridal veil, a sterile product which is fixed over the graft with staples.

Silicone net dressings have also been used successfully to prevent lifting and adherence of skin grafts to the dressings, prevent pain and promote healing. Mepitel One is a sterile, transparent, and flexible wound contact layer consisting of perforated polyurethane film coated with Safetac soft silicone adhesive on one side. Mepitel One is available in various sizes and can be left in place for several days depending on the wound/skin condition.

Evaluation of burns will be performed at Baseline. Skin graft assessment will be performed at Day 7 and Day 14. End of study will be considered the time that graft is considered to have >95% take.


Recruitment information / eligibility

Status Completed
Enrollment 43
Est. completion date December 2011
Est. primary completion date December 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Inclusion Criteria

1. Subjects presenting with 1% - 25% Total Body Surface Area (TBSA) deep partial or full-thickness burns requiring skin graft

2. At least 1%-10% TBSA is available for grafting that can be considered for study site selection (must have intact, healthy peri-wound area around entire portion of this burned site)

3. Both genders with age =18 years but < 70 years

4. Signed informed consent

Exclusion Criteria:

1. Subjects with chronic wounds

2. Subjects who are on mechanical ventilation

3. Subjects with dermatologic skin conditions or necrotizing disorders

4. Diagnosed underlying disease(s) (HIV/AIDS, cancer and severe anaemia)judged by the investigator to be a potential interference in the treatment

5. Subjects treated with systemic glucocorticosteroids, except subjects taking occasional doses or doses less than 10 mg prednisolon/day or equivalent

6. Use of immunosuppressive agents, radiation or chemotherapy within the past 30 days

7. Known allergy/hypersensitivity to any of the components of the investigational products

8. Subjects with physical and/or mental conditions that are not expected to comply with the investigation

9. Participation in other clinical investigation(s) within 1 month prior to start of the investigation

10. Previously randomised to this investigation

11. Pregnancy

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
Mepitel One
Dressing

Locations

Country Name City State
United States Joseph M. Still Research Foundation, Inc. Augusta Georgia
United States 5028 Delp Bldg, Mail stop 1011 Kansas City Kansas
United States University Foundation for Education & Research, Inc Tampa Florida
United States Natham Speare Regional Burn Treatment Ctr., Crozer Chester Medical Center Upland Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Molnlycke Health Care AB

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary VAS Score for Pain Before Dressing Removal Pain was measured with Visual Analogue Scale (VAS)(100 mm) measuring from 0 = "no pain" at one end to 100 = "most intense pain imagaginable" at the other end. At visit 6, day 7 Yes
Primary VAS Score for Pain During Dressing Removal Pain when half of the study product(s) has been removed measued with Visual Analogue Scale (VAS).0 = "no pain" till 100 = "worst pain". Visit 6, day 7 Yes
Primary VAS Score for Pain After Dressing Removal Pain after the dressing removal measued with Visual Analogue Scale (VAS).0 = "no pain" till 100 = "worst pain". Visit 6, day 7 Yes
See also
  Status Clinical Trial Phase
Completed NCT01785784 - Efficacy and Safety Study of rhGM-CSF Gel to Treat Deep 2nd Thickness Burn Phase 4
Completed NCT01553708 - Effect of EGF With Silver Sulfadiazine Cream Compared With Silver Zinc Sulfadiazine Cream for Treatment of Burn Wound Phase 2/Phase 3